In the face of tariffs, FDA-approved drug manufacturing deals are shifting to Europe
In 2025, biopharma companies increasingly invested in Europe-based contract manufacturing for FDA-approved drugs compared to US-based providers, despite US import tariffs on pharmaceuticals.
